Hemolytic disease of the fetus and newborn (HDFN) affects 3/100,000 to 80/100,000 patients yearly and can cause severe anemia and hyperbilirubinemia. Recombinant human erythropoietin has been used as an adjunct therapy in patients with HDFN and hypo-regenerative anemia in the setting of receiving intrauterine blood transfusions. This case describes a patient with HDFN, in which the family were Jehovah Witnesses, and blood transfusions were declined. The patient had symptomatic anemia with a hematocrit nadir of 18.6%. The patient was successfully treated with recombinant human erythropoietin, ferrous sulfate, and folic acid, avoiding the need for transfusion.

中文翻译：

---

无血液制品治疗胎儿和新生儿溶血病一例。

胎儿和新生儿溶血病 (HDFN) 每年影响 3/100,000 至 80/100,000 名患者，可导致严重贫血和高胆红素血症。重组人促红细胞生成素已被用作接受宫内输血的 HDFN 和低再生性贫血患者的辅助治疗。该病例描述了一名 HDFN 患者，其家人都是耶和华见证人，输血遭到拒绝。该患者有症状性贫血，血细胞比容最低值为 18.6%。该患者成功接受了重组人促红细胞生成素、硫酸亚铁和叶酸的治疗，避免了输血的需要。